Charles River Bolsters CRO Services With Frontage Bioanalysis, DMPK Buy
CRL has more than doubled off its 52-week low of $146.195.
Summary
Charles River agreed to acquire Frontage's bioanalysis and DMPK businesses for about $470 million, with potential additional payments of up to $75 million, adding lab-service capabilities to its drug-discovery and development franchise. The acquired businesses represented about 40% of Frontage's 2025 revenue of $256.7 million. Charles River will finance the deal through a credit facility and available cash. The move comes days after Charles River beat Q3 expectations and raised 2026 guidance, giving it momentum and balance-sheet room to bolt on capabilities. Frontage's bioanalysis and DMPK work sits squarely in the outsourced lab niche Charles River already serves, so this is a tuck-in that broadens its early-stage service menu rather than a thesis-changing bet. Charles River is participating in a consortium with Hangzhou Tigermed Consulting and Song Li to take Frontage private.
At the time of this announcement, CRL was trading at $337.44 on NYSE in the Life Sciences sector, with a market capitalization of approximately $16.1B. The 52-week trading range was $146.20 to $379.63. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.